| Literature DB >> 30737793 |
Alexandra C Istl1,2, Jessica M Ruck3, Carol D Morris4, Adam S Levin4, Christian F Meyer5, Fabian M Johnston3,6.
Abstract
New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.Entities:
Keywords: chemotherapy; localized; resectable; soft tissue sarcoma
Mesh:
Year: 2019 PMID: 30737793 DOI: 10.1002/jso.25401
Source DB: PubMed Journal: J Surg Oncol ISSN: 0022-4790 Impact factor: 3.454